0001883085 2025-01-01 2025-12-31 0001883085 us-gaap:CommonClassAMember 2025-01-01 2025-12-31 0001883085 pgy:CommonStockWarrantsMember 2025-01-01 2025-12-31 0001883085 us-gaap:CommonClassAMember 2026-02-28 0001883085 us-gaap:CommonClassBMember 2026-02-28 0001883085 us-gaap:PreferredClassAMember 2026-02-28 0001883085 2025-06-30 shares iso4217:USD 0001883085 2025 FY true 10-K/A true 2025-12-31 --12-31 false 001-41430 Pagaya Technologies Ltd. L3 98-1704718 335 Madison Ave 16th Floor New York NY 10017 646 710-7714 Class A Ordinary Shares, no par value PGY NASDAQ Warrants to purchase Class A Ordinary Shares PGYWW NASDAQ No No Yes Yes Large Accelerated Filer false false true false false 71556702 11288577 2027147 1113790997 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> Pagaya Technologies Ltd. (“Pagaya” or the “Company”) is filing this Amendment No. 1 on Form 10-K/A (this “Amendment”) to amend its Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 2, 2026 (the “Original Report” or the “2025 Annual Report on Form 10-K”). This Amendment is being filed for the purpose of including the information required by Items 10 through 14 of Part III of Form 10-K (the “Part III Information”) not included in the Original Report. The Part III Information was previously omitted from the Original Report in reliance on General Instruction G(3) to Form 10-K, which provides that the Part III Information may be either incorporated by reference from the registrant’s definitive proxy statement or included in an amendment to Form 10-K, in either case filed with the SEC not later than 120 days after the end of the fiscal year covered by the Form 10-K. We are filing this Amendment to include the Part III Information in the Original Report because our definitive proxy statement for our 2026 annual general meeting of shareholders containing this information will not be filed before the 120th day after the end of our last fiscal year. As such, this Amendment hereby amends and supplements Items 10 through 14 of Part III of the Original Report and amends and updates the Form 10-K cover page (primarily to update the number of shares of Common Stock outstanding to April 20, 2026). In addition, in accordance with applicable SEC rules, Item 15 of Part IV of the Original Report has been supplemented to include currently dated certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Except as described above, this Amendment does not amend, update or change any other items or disclosures in the Original Report and does not purport to reflect any information or events subsequent to the filing of the Original Report. As such, this Amendment speaks only as of the date the Original Report was filed, and we have not undertaken herein to amend, supplement or update any information contained in the Original Report to give effect to any subsequent events. true <div style="margin-bottom:10pt;text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards are typically granted in March as part of the annual total compensation review for senior leaders and other employees and are approved by the Compensation Committee on or before the grant date. The Compensation Committee’s general practice is to complete its annual executive compensation review and determine performance goals and target compensation for our named executive officers, following which the Committee approves equity awards for named executive officers as well as any other equity award recipients. On occasion, the Compensation Committee may grant equity </span></div>awards outside of our annual grant cycle for new hires, promotions, recognition, retention, or other purposes. While the Compensation Committee has discretionary authority to grant equity awards outside of the cycle described above, the Committee does not have a practice or policy of granting equity awards in anticipation of the release of material non-public information and does not time the release of material non-public information in coordination with grants of equity awards in a manner that intentionally affects the value of executive compensation. <div style="margin-bottom:10pt;text-indent:20pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Equity awards are typically granted in March as part of the annual total compensation review for senior leaders and other employees and are approved by the Compensation Committee on or before the grant date. The Compensation Committee’s general practice is to complete its annual executive compensation review and determine performance goals and target compensation for our named executive officers, following which the Committee approves equity awards for named executive officers as well as any other equity award recipients. On occasion, the Compensation Committee may grant equity </span></div>awards outside of our annual grant cycle for new hires, promotions, recognition, retention, or other purposes. While the Compensation Committee has discretionary authority to grant equity awards outside of the cycle described above, the Committee does not have a practice or policy of granting equity awards in anticipation of the release of material non-public information and does not time the release of material non-public information in coordination with grants of equity awards in a manner that intentionally affects the value of executive compensation. true While the Compensation Committee has discretionary authority to grant equity awards outside of the cycle described above, the Committee does not have a practice or policy of granting equity awards in anticipation of the release of material non-public information and does not time the release of material non-public information in coordination with grants of equity awards in a manner that intentionally affects the value of executive compensation. true false